Price
$12.21
Increased by +2.35%
Dollar Volume
3.30 M
ADR%
6.03
Earnings Report Date (estimate)
Jun 29, 20 (-0.31)
Market Cap.
311.15 M
Shares Float
24.59 M
Shares Outstanding
25.48 M
Beta
0.49
Price / Earnings
-10.68
BPR
317.74
20D Range
9.38 12.25
50D Range
9.31 12.25
200D Range
4.67 15.12
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 16, 22 -0.38
Decreased by -52.00%
-0.30
Decreased by -26.67%
Aug 12, 22 -0.33
Decreased by -13.79%
0.51
Decreased by -164.71%
Mar 25, 22 -0.36
Increased by +2.70%
-0.30
Decreased by -20.00%
Nov 12, 21 -0.30
Increased by +16.67%
-0.28
Decreased by -7.14%
Jul 30, 21 -0.25
Increased by +39.02%
-0.30
Increased by +16.67%
May 14, 21 -0.29
Increased by +67.78%
-0.29
Mar 31, 21 -0.37
Increased by +58.89%
-0.37
Oct 23, 20 -0.36
Increased by +60.00%
-0.44
Increased by +18.18%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 45.00 K
Decreased by -80.69%
-9.47 M
Decreased by -47.50%
Decreased by -21.05 K%
Decreased by -663.73%
Jun 30, 22 45.00 K
Decreased by -83.08%
-7.77 M
Decreased by -54.69%
Decreased by -17.26 K%
Decreased by -814.39%
Mar 31, 22 940.00 K
Increased by +51.13%
-5.13 M
Increased by +3.59%
Decreased by -545.64%
Increased by +36.21%
Dec 31, 21 23.00 K
Increased by +N/A%
-8.01 M
Decreased by -35.96 K%
Decreased by -34.83 K%
Decreased by N/A%
Sep 30, 21 233.00 K
Increased by +N/A%
-6.42 M
Decreased by -115.84 K%
Decreased by -2.76 K%
Decreased by N/A%
Jun 30, 21 266.00 K
Increased by +N/A%
-5.02 M
Decreased by -8.56%
Decreased by -1.89 K%
Decreased by N/A%
Mar 31, 21 622.00 K
Increased by +N/A%
-5.32 M
Increased by +6.17%
Decreased by -855.31%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-22.21 K
Increased by +99.52%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.